Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:20 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 8,137 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Period 1 Clear all

Conditions: Allergic Conjunctivitis
Interventions: AC-170 0.05%, AC-170 0.1%, AC-170 0.24%, AC-170 0%; Drug
Lead sponsor: Aciex Therapeutics, Inc.; Industry
Eligibility: 10 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Tiotropium/Salmeterol, Salmeterol, Placebo, Tiotropium; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 16
States / cities: Anniston, Alabama • Mobile, Alabama • Clearwater, Florida + 10 more

Conditions: Stress
Interventions: Placebo Control Form 1, Relaxation Active Study Product 1.1, Placebo Control Form 2, Relaxation Active Study Product 2.1, Placebo Control Form 3, Relaxation Active Study Product 3.1, Placebo Control Form 4, Relaxation Active Study Product 4.1, Relaxation Active Study Product 4.2; Dietary Supplement
Lead sponsor: Radicle Science; Industry
Eligibility: 21 Years to 105 Years
Enrollment: 1,700 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Del Mar, California

Conditions: Multiple Sclerosis
Interventions: Bodyweight training; Behavioral
Lead sponsor: Holy Name Medical Center, Inc.; Other
Eligibility: 40 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Teaneck, New Jersey

Conditions: Norovirus Infections
Interventions: VXA-G1.1-NN; Biological
Lead sponsor: Vaxart; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Cypress, California

Conditions: Chronic Kidney Disease
Interventions: GCS-100; Drug
Lead sponsor: La Jolla Pharmaceutical Company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 5
States / cities: Tempe, Arizona • La Mesa, California • Denver, Colorado + 2 more

Conditions: Inflammation
Interventions: Diet and Physical Activity; Behavioral
Lead sponsor: University of South Carolina; Other
Eligibility: 30 Years and older
Enrollment: 438 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Obstructive Sleep Apnea (OSA)
Interventions: Case Management; Other
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Fontana, California

Conditions: Brain Injuries, Traumatic
Interventions: Safe@Home Intervention Group, Usual Care Group; Behavioral · Other
Lead sponsor: Shepherd Center, Atlanta GA; Other
Eligibility: 18 Years to 99 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Healthy
Interventions: Cilostazol 50 mg Tablets, Pletal®; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 2
States / cities: East Grand Forks, Minnesota • Fargo, North Dakota

Conditions: Schizophrenia
Interventions: BI 409306 100 mg QD, BI 498306 50 mg QD, Placebo, BI 498306 25 mg QD, BI 409306 10 mg QD; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 518 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 24
States / cities: Little Rock, Arkansas • Cerritos, California • Garden Grove, California + 18 more

Conditions: Psychological Stress
Interventions: Psychological education program for nurses; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Clinical Pharmacology, Healthy Volunteer Study
Interventions: Placebo, Pomalidomide, Moxifloxacin; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Atopic Dermatitis
Interventions: Etrasimod 1 mg, Etrasimod 2 mg, Etrasimod matching placebo; Drug
Lead sponsor: Arena Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 35
States / cities: Tucson, Arizona • Canoga Park, California • Fountain Valley, California + 29 more

Conditions: Cystic Fibrosis
Interventions: LUM/IVA; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 6 Years and older
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 37
States / cities: Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 34 more

Conditions: ADHD - Combined Type
Interventions: Methylphenidate, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 6 Years to 40 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Glioblastoma
Interventions: CTX-009, CTX-471; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Acne Vulgaris
Interventions: YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 14 Years to 45 Years · Female only
Enrollment: 534 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2004
U.S. locations: 27
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 23 more

Conditions: Fibrodysplasia Ossificans Progressiva (FOP)
Interventions: Non-Interventional; Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: Not listed
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Tarrytown, New York

Conditions: Healthy
Interventions: [14C]PF-05221304; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Heart Repolarization
Interventions: Naltrexone HCl/bupropion HCl, Placebo, Moxifloxacin; Drug · Other
Lead sponsor: Orexigen Therapeutics, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Autism Spectrum Disorder
Interventions: Robot-mediated Intervention; Behavioral
Lead sponsor: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.; Other
Eligibility: 4 Years to 8 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Stomach Cancer Stage IV, Esophagus Cancer, Stomach Cancer
Interventions: Ivonescimab, 5-Fluorouracil, Oxaliplatin, Leucovorin; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Santa Monica, California • Boston, Massachusetts

Conditions: Smoking
Interventions: naltrexone, varenicline, placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Search by objective public record fields.

Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model

Tiotropium/Salmeterol Inhalation Powder in COPD

Radicle Relaxation 24: A Study of Health and Wellness Products on Stress and Related Health Outcomes

Effects of a Weight Based Training Program on MS Patients

A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Administered to Healthy Adult Volunteers

A Phase 2 Extension Study of Study GCS-100-CS-4002

Diet & Activity Community Trial: High-Risk Inflammation

CPAP Population Management

Safe@Home: A Self-Management Program for Individuals With TBI and Their Families

Cilostazol 50 mg Tablets Under Fasting Conditions

A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.

Waitlist-controlled Trial of a Psychological Education Program for Nurses

A Phase 1 QT Study in Healthy Male Subjects

A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis

Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor

Multimodal Brain Imaging of the Neural Effects of Methylphenidate in Patients With ADHD

Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma

Evaluate Safety and Efficacy of an OC Preparation vs Placebo for 6 Treatment Cycles in Women With Moderate Acne.

A Non-Interventional Study of Clinical Characteristics and Mortality of US Patients With Fibrodysplasia Ossificans Progressiva (FOP)

Single-dose Study of [14C]PF-05221304 Metabolism and Excretion in Healthy Adult Male Subjects

Study to Evaluate the Effect of Naltrexone and Bupropion Extended-Release Combination on Cardiac Repolarization in Healthy Participants

Robot-Mediated Intervention for Children With Autism Spectrum Disorders

Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA

The Effect of Naltrexone and Varenicline on Alcohol-Mediated Smoking Lapse